Target Price | $79.75 |
Price | $54.09 |
Potential |
47.44%
register free of charge
|
Number of Estimates | 16 |
16 Analysts have issued a price target Cytokinetics, Incorporated 2025 .
The average Cytokinetics, Incorporated target price is $79.75.
This is
47.44%
register free of charge
$107.00
97.82%
register free of charge
$60.00
10.93%
register free of charge
|
|
A rating was issued by 18 analysts: 14 Analysts recommend Cytokinetics, Incorporated to buy, 4 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Cytokinetics, Incorporated stock has an average upside potential 2025 of
47.44%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 7.53 | 10.34 |
92.04% | 37.30% | |
EBITDA Margin | -6,431.74% | -5,161.53% |
1,826.47% | 19.75% | |
Net Margin | -8,506.49% | -5,822.49% |
1,481.10% | 31.55% |
16 Analysts have issued a sales forecast Cytokinetics, Incorporated 2024 . The average Cytokinetics, Incorporated sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Cytokinetics, Incorporated EBITDA forecast 2024. The average Cytokinetics, Incorporated EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Cytokinetics, Incorporated Analysts have issued a net profit forecast 2024. The average Cytokinetics, Incorporated net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -5.45 | -5.12 |
25.87% | 6.06% | |
P/E | negative | |
EV/Sales | 589.75 |
16 Analysts have issued a Cytokinetics, Incorporated forecast for earnings per share. The average Cytokinetics, Incorporated <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Cytokinetics, Incorporated stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Cytokinetics, Incorporated...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.